Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion (NASDAQ: ESPR) announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on November 16, 2022, at 5:20 AM (EST). The presentation will include a live audio webcast, accessible via the company's website, with a replay available approximately two hours post-event. Esperion is dedicated to developing innovative medications aimed at lowering cholesterol, especially for patients with unmet needs. For further details, visit www.esperion.com.
Esperion (NASDAQ: ESPR) announced significant developments in its recent press release. The CLEAR Outcomes trial completed its last patient visit in October 2022, with topline results expected in January 2023 and full results in March at the American College of Cardiology event. In Q3 2022, U.S. net product revenue for NEXLETOL® and NEXLIZET® grew by 28% year-over-year to $14.0 million. Overall revenue for Q3 reached $19.0 million, reflecting a 32% increase versus 2021. However, the company reported a net loss of $55.1 million for the quarter.
Esperion (NASDAQ: ESPR) will host a virtual research and development day on November 9, 2022, featuring renowned scientists C. Michael Gibson and Peter Libby. The event will cover Esperion's investigational programs and future growth prospects, including the CLEAR Outcomes trial for bempedoic acid and advancements in its ACLYi platform targeting cardiovascular and metabolic diseases. The trial includes over 14,000 patients and has recorded significant cardiovascular events. This session will provide insights into Esperion's strategic direction and innovative approaches.
Esperion announced the granting of 14,000 restricted stock units (RSUs) to five new employees on October 18, 2022. This action falls under the 2017 Inducement Equity Incentive Plan, aimed at incentivizing individuals who weren't previously associated with the company. The RSUs will vest over four years, with 25% becoming exercisable on the one-year anniversary of their vesting commencement date and the remaining 75% vesting quarterly thereafter, contingent on ongoing employment. Esperion focuses on developing oral LDL-cholesterol lowering medications.
Esperion (NASDAQ: ESPR) is set to announce its third quarter 2022 financial results on November 1, 2022, before U.S. markets open. Following the release, company management will host a webcast at 8:00 a.m. ET to discuss the results and business progress. Interested parties can pre-register for the webcast through their official website, where a replay will also be available approximately two hours after the call, archived for 90 days.
Esperion is focused on developing innovative cholesterol-lowering medications for patients with unmet needs.
Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 9:20 AM (ET). He will also participate in the H.C. Wainwright Annual Global Investment Conference from September 12-14, 2022, with a presentation scheduled for September 13 at 11:30 AM (ET). Both events will include a presentation format and one-on-one meetings, with webcasts available. Esperion focuses on developing innovative medicines for cholesterol management, including NEXLETOL® and NEXLIZET®.
Esperion (NASDAQ: ESPR) announced that bempedoic acid (NEXLETOL) is now recommended by the American College of Cardiology (ACC) as a vital non-statin therapy for LDL-cholesterol lowering in managing atherosclerotic cardiovascular disease (ASCVD). This update highlights the need for alternative options for patients who cannot achieve LDL-C goals with statins alone. Based on Phase III trial evidence, bempedoic acid has shown a 24.5% reduction in LDL-C levels. The ACC endorsement, along with other recommendations, supports the importance of non-statin therapies in clinical practice.
Esperion (NASDAQ: ESPR) granted 66,000 restricted stock units (RSUs) to 13 new employees on August 2, 2022, through its 2017 Inducement Equity Incentive Plan. This plan targets individuals who were not previous employees or directors, providing inducements for joining Esperion. The RSUs will vest 25% after one year and the remaining 75% in twelve equal quarterly installments, contingent upon continued employment. Esperion specializes in developing oral LDL-cholesterol lowering medications tailored for patients unmet by existing options.
Esperion reported significant progress in its CLEAR Outcomes Trial, achieving 100% of targeted MACE-4 events, with topline results expected in Q1 2023. In Q2 2022, U.S. product revenue for NEXLETOL and NEXLIZET increased by 28% year-over-year to $13.6 million, while total revenue stood at $18.8 million, reflecting a 54% decline from Q2 2021 due to a one-time payment last year. R&D expenses rose to $32.4 million, driven by trial costs, while SG&A expenses fell 36% to $29.6 million. The company reported a net loss of $66.3 million, improving loss per share to $1.05.
Esperion (NASDAQ: ESPR) announced the formation of its Scientific Advisory Board (SAB) on July 25, 2022. The board features esteemed experts in atherosclerosis and cardiovascular diseases, who will guide the company's research and development strategy. CEO Sheldon Koenig emphasized the importance of the SAB's role, especially as the CLEAR Outcomes trial results are imminent. Notable co-chairs include Peter Libby and Joanne Foody. The company aims to optimize its marketed products and pipeline assets, including an oral PCSK9 inhibitor.